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Abstract
Background: The epidemiology of cannabinoid-related cancerogenesis has not been studied with cutting edge epidemiological techniques. Building on earlier bivariate papers in this series we aimed to conduct pathfinding studies to
address this gap in two tumours of the reproductive tract, prostate and ovarian cancer.
Methods: Age-standardized cancer incidence data for 28 tumour types (including “All (non-skin) Cancer”) was
sourced from Centres for Disease Control and National Cancer Institute using SEER*Stat software across US states
2001–2017. Drug exposure was sourced from the nationally representative household survey National Survey of Drug
Use and Health conducted annually by the Substance Abuse and Mental Health Services Administration 2003–2017
with response rate 74.1%. Federal seizure data provided cannabinoid concentration data. US Census Bureau provided
income and ethnicity data. Inverse probability weighted mixed effects, robust and panel regression together with
geospatiotemporal regression analyses were conducted in R. E-Values were also calculated.
Results: 19,877 age-standardized cancer rates were returned. Based on these rates and state populations this
equated to 51,623,922 cancer cases over an aggregated population 2003–2017 of 124,896,418,350. Inverse probability
weighted regressions for prostate and ovarian cancers confirmed causal associations robust to adjustment. Cannabidiol alone was significantly associated with prostate cancer (β-estimate = 1.61, (95%C.I. 0.99, 2.23), P = 3.75 × 10− 7).
In a fully adjusted geospatiotemporal model at one spatial and two temporal years lags cannabidiol was significantly
independently associated with prostate cancer (β-estimate = 2.08, (1.19, 2.98), P = 5.20 × 10− 6). Cannabidiol alone
was positively associated with ovarian cancer incidence in a geospatiotemporal model (β-estimate = 0.36, (0.30, 0.42),
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P <  2.20 × 10− 16). The cigarette: THC: cannabidiol interaction was significant in a fully adjusted geospatiotemporal
model at six years of temporal lag (β-estimate = 1.93, (1.07, 2.78), P = 9.96 × 10− 6). Minimal modelled polynomial
E-Values for prostate and ovarian cancer ranged up to 5.59 × 1059 and 1.92 × 10125. Geotemporospatial modelling
of these tumours showed that the cannabidiol-carcinogenesis relationship was supra-linear and highly sigmoidal
(P = 1.25 × 10− 45 and 12.82 × 10− 52 for linear v. polynomial models).
Conclusion: Cannabinoids including THC and cannabidiol are therefore important community carcinogens additive to the effects of tobacco and greatly exceeding those of alcohol. Reproductive tract carcinogenesis necessarily
implies genotoxicity and epigenotoxicity of the germ line with transgenerational potential. Pseudoexponential and
causal dose-response power functions are demonstrated.
Keywords: Cannabis, Cannabinoid, Δ9-tetrahydrocannabinol, Cannabigerol, Cannabidiol, Mechanisms, Congenital
anomalies, Oncogenesis, Genotoxicity, Epigenotoxicity, Chromosomal toxicity, Multigenerational genotoxicity,
Transgenerational teratogenicity, Dose-response relationship, Supra-linear dose response, Sigmoidal dose-response

Background
Cannabis has been linked with cancers at many sites
including head and neck, brain, lung, larynx, prostate,
testis, cervix and urothelium by previous studies [1–18].
However uncertainty on many of these points persists as
other studies with conflicting results also appear both in
the literature [4, 19, 20] and in reviews [16, 21–24].
The most strongly documented link between cannabis
and cancer is for testicular cancer where several recent
studies have confirmed an association [3, 8–10] and
dose-response effects have been demonstrated [3, 8, 10].
Endocrine disruption through such events as low birthweight, short gestation, tall stature, maternal bleeding,
twinship, first position in the sibship and small sibship
has also been linked with the development of testicular
cancer. Since the testis houses the male germ cell epithelium it is conceivable that genomic or epigenomic damage incurred by the male germ cells may be passed along
to subsequent generations.
This possibility is confirmed by published reports linking prenatal cannabis exposure with paediatric cancer
incidence including rhabdomyosarcoma [16], childhood neuroblastoma [15] and leukaemia particularly
non-lymphoblastic leukaemia [17, 19] which together
demonstrate evidence of inheritable mutagenicity and
carcinogenicity in human populations [25, 26]. The
importance of mutagenicity, carcinogenicity and heritability was underscored by a recent report showing that
breast, thyroid, liver and pancreatic cancers and acute
myeloid leukaemia along with three chromosomal trisomies (21, 18 and 13), Turners syndrome and Deletion
22q11.2 were increased causally and across space-time
in relation to cannabis use [27]. Other reports show that
cannabis exposure is a likely cause and driver of rising
paediatric cancer rates [28] including the commonest
childhood cancer acute lymphoid leukaemia [28].
Cannabidiol is of particular concern as it is often
thought to be relatively safe, is widely available in many

jurisdictions and its known genotoxicity [29–37] and epigenotoxicity [38–48] is generally unknown and ignored.
Prostate cancer was previously found to be greatly elevated by current cannabis exposure with an odds ratio of
4.7 (95%C.I. 1.4, 15.5) [7]. Intriguingly endocrine disruption was identified as one possible mechanism to explain
this relationship [7]. Cannabis is a well established endocrine disruptor [49–59]. Whilst there are no extant papers
documenting the relationship of cannabinoid exposure
to ovarian cancers oocytes have been shown to be highly
sensitive to cell death during cell division under the influence of cannabinoids [60] and the ovary is also known to
be highly sensitive to inhibitors of mitochondrial metabolism a role which several cannabinoids including cannabidiol have long been known to play [36, 37, 61–65].
Earlier reports in this series have considered the impact
of substance and cannabinoid exposure on a panel of 28
common cancers across USA [66, 67]. Prostate and ovarian cancer were found to be particularly associated with
cannabidiol exposure in these bivariate studies [66, 67].
It was the purpose of this paper to investigate this relationship further in a multivariable context using the tools
of causal inferential and geospatial modelling and to
examine the impacts of limited mathematical modelling
on some of the important models to proceed from these
regression studies. This is done both to provide detailed
information on these two tumours and to demonstrate an
analytical and causal inferential pipeline for the further
exploration of such rich epidemiological datasets.

Methods
Data

Rates of age-adjusted cancer rates by state and year
and cancer type was taken from the Surveillance, Epidemiology and End Results (SEER) database from the
Centres for Disease Control (CDC) Atlanta, Georgia
and the National Cancer Institute (NCI) and from the
National Program of Cancer Registries (NPCR) and
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SEER Incidence US Cancer Statistics Public Use Database 2019 submission covering years 2001–2017 using
the SEER*Stat software [68]. The focus of this study was
28 of the most common cancers (as listed below). This
includes the category all non-skin cancer (called All
Cancer in this report). This was joined with drug use
cross-tabulation data across USA by state and year from
the National Survey of Drug Use and Health (NSDUH)
Restricted-Use Data Analysis System (RDAS) of the Substance Use and Mental Health Data Archive (SAMHDA)
held by the Substance Use and Mental Health Services
Administration (SAMHSA) 2003–2017 [69]. Thus the
overlap period between the cancer and drug exposure
datasets was 2003–2017 which therefore became the
period of analysis. The variables of interest were last
month cigarettes, last year alcohol use disorder (AUD),
last month cannabis, last year non-medical use of opioid analgesics (Analgesics) and last year cocaine. Quintiles of substance exposure were calculated for each
year numbered from one, the lowest quintile, to five
the highest exposure quintile. Data on median household income, ethnicity and population by state and year
was sourced directly from the US Census bureau via the
tidycensus package [70] in R including linear interpolation for missing years. The ethnicities of interest were
Caucasian-American, African-American, HispanicAmerican, Asian-American, American Indian / Alaska
Native (AIAN) and Native Hawaiian / Pacific Islander
(NHPI). Data on cannabinoid concentration across
USA was taken from reports published by the US Drug
Enforcement Agency (DEA) for the five cannabinoids
Δ9-tetrahydrocannabinol (THC), cannabigerol (CBG),
cannabichromene (CBC), cannabinol (CBN), and cannabidiol (CBD) [71–73]. It was multiplied by state level
cannabis use to provide an estimate of state level exposure. Quintiles of cannabinoid exposure were calculated on the whole period considered in aggregate. Age
adjusted case numbers were derived by multiplying the
age-adjusted cancer rate in each state and year by the
population of that state and dividing it by 10,000.
Statistical analysis

Data was processed in R-Studio version 1.3.1093 (2009–
2020) based upon R version 4.0.3 (2020-10-10). Covariates were log transformed guided by the Shapiro-Wilks
test. Data was manipulated using the “dplyr” package in
the “tidyverse” [74]. Graphs were drawn in ggplot2 from
tidyverse [74, 75] and maps and graphs were drawn in
R-Base, ggplot2 and “sf ” (simple features) [76]. Some
colour palettes employed the viridis and plasma palettes
taken from the package “Viridis” [77] and several palettes were originally designed for this project. Bivariate
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maps were drawn using colorplaner two way colour
matrices [78]. All maps and graphs are original and have
not been previously published. General additive models (GAM) were computed using the package “mgcv”
[79, 80]. Models were compared using the Anova test in
R-base.
Regression models

Bivariate linear trends were computed with linear regression from R-Base. Repeated measures mixed effects
regression was conducted using the package “nlme” using
state as the random effect [81]. Robust generalized linear
regression was conducted in the R “survey” package again
using state as the identity variable [82]. Panel regression
was conducted using package “plm” using a space-time
method [83]. In each case model reduction from initial to
final models was by the classical method of serial deletion
of the least significant term.
Geotemporospatial regression was conducted using
the spreml (spatial panel random effects maximum
likelihood) function from the “splm” (spatial panel linear modelling) package [84]. Spatial weights matrices
describing the spatial relationship between states were
computed from edge and corner (“queen”) relationships
computed from the package “spdep” [85] and edited
as described. Model specification was checked by the
previously described reverse method [86]. Four spatial
coefficients are calculated in full spatial panel random
error maximum likelihood (spreml) models as phi, psi,
rho and lambda corresponding to the terms for random
effects, serial autocorrelation effects, spatial coefficient
and autocorrelation of the spatial coefficients respectively [87]. When verifying model specification by the
reverse method non-significant error terms are deleted
from the fully specified (error = semsrre + lag) model
[86]. This was the procedure used in the present report.
Such procedures allow for fine control of the structure of
the error terms.
Different forms of regression were used for the following reasons. Mixed effects modelling has the advantage over linear modelling that repeated measurements
can be considered from the same region. Inverse probability weighting is possible in mixed effects, robust and
panel modelling but not in spatial models. Mixed effects,
panel and spatial models allow the calculation of a model
standard deviation so E-Values can be calculated from
such models. Lagging can be applied in panel and spatial
panel models but not in mixed effects or robust models.
Instrumental variables can be employed in panel models but not in spatial panel models. Spatial panel models allow the use of both spatially and temporally lagged
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variables as well as spatially and temporally lagged variables simultaneously. Hence it was felt that the use of several different regression model types would allow a broad
and comprehensive overview of the analyses and allow
result verification by several alternative methods.
Simultaneous multiple model analysis

This was conducted in the tidyverse package “purrr” [74]
using tidy and glance from package “broom” [88] using
established nest-map-unnest workflows. In this way a
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deviation of that data series will change its mean to zero
and its standard deviation to 1. This is a standard statistical transformation known as the z-transformation. In
this case an extended z-transformation procedure was
performed whereby the mean of the predicted data series
for the cancer rate was added to the mean after z-transformation and the new standard deviation was set at the
ratio of the median of the raw data series to the median
of the fitted values from the model. Hence the final predicted value conversion formula appears as follows:

(
)
(
))
(
(
(
(
))))
(
Recalibrated_Result = (Res − mean(Res))∕ (sd(Res))∕ sd(FVV ) ∗ median SPDSST $CancRt ∕median(FVV )
+ mean SPDSST $CancRt

whole long dataset providing data on many cancers could
be analyzed in a single analysis run at one time.
Causal inference

Causal inference was addressed in two ways. Firstly
inverse probability weighting (IPW) was conducted on
all mixed effects, robust and panel models which had
the effect of equilibrating exposure across all observed
groups. IPW were computed from the R-package “ipw”
[89]. Inverse probability weighting transforms an observational dataset into a pseudo-randomized dataset so
that it becomes appropriate to draw inferences as to truly
causal relationships. Secondly E-values were computed
using the R-package “EValue” [90] both from count data
and from regression equations using the parameter estimate, its standard error and the standard model deviation
[91–93]. E-Values were computed both for regression
models and for the predicted output from fitted models. E-Values were computed for mixed effects, panel and
spatial panel models [92–95]. Minimum E-Values above
1.25 are said to suggest causal relationships [91].
Predictive spatial modelling

Selected spatial panel models were chosen for predictive analysis as described. Spatial panel (spreml) model
objects include a vector of model predicted values ($fitted.values). Matrix multiplication was used to multiply
101 vectors, comprising percentiles zero to 100 of exposure to the cannabinoids THC, cannabigerol and cannabidiol by the model parameter coefficients to produce
model predicted values. Terms which did not include
cannabinoids were set at their mean value for this exercise and the intercept coefficient was set at one. In each
case the resulting predictions were outside and below the
range of the cancer incidence, which was unsurprising as
the models themselves included both log and lag terms.
The z-transformation is often used in statistics to correct variable distributions. Subtracting the mean of a
data series from the values and dividing by the standard

where Res is the raw results from matrix multiplication,
mean is the average, sd is the standard deviation, median
is the median, SPDSST is the spatial panel space-time
dataset for the cancer concerned, FVV is the fitted values from the model, CancRt is the observed age-adjusted
cancer rate for that tumour reported from SEER and $ is
a placeholder for the dataframe signifying the variable
name. The reported analysis of model predictions was
performed on the Recalibrated Results after application
of this extended z-transformation conversion formula.
Spatially and temporally lagged modelling

As it is well known that there has been a spatiotemporal
progression of the re-scheduling of cannabis products and
availability across USA over the last decade it was of interest to see if accounting for spatially and temporally lagged
effects affected the outcomes of the analyses or the main
conclusions. Preliminary studies suggested that single
spatial lags were appropriate. Cancer is also a time lagged
disease so there were several reasons for wanting to consider a series of temporal lags to investigate the effect that
temporal lagging had on model progression. Temporal
lagging was used in both panel and spatiotemporal models whilst spatial lagging was restricted to spatial models.
P < 0.05 was considered significant throughout.
Data availability

Data, including R-code, ipw weights and spatial weights
has been made freely available through the Mendeley
Data repository online and can be accessed at https://doi.
org/10.17632/dt4jbz7vk4.1
Ethics

Ethical approval for this study was granted from the
University of Western Australia Human Research Ethics Committee approval number on 7th January 2020
RA/4/20/7724.
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Results
The cancers upon which we chose to focus our attention were chosen because they were relatively common
or because they involved tissues which had been implicated in the literature with cannabinoid activities. For
this reason cancers of the male and female reproductive
tract were well represented amongst the cancers chosen
for this study. The list in alphabetical order comprises
tumours of: acute lymphoid leukaemia (ALL), acute
myeloid leukaemia (AML), bladder, brain, breast, cervix,
chronic lymphoid leukaemia (CLL), chronic myeloid
leukaemia (CML), colorectum, oesophagus, Hodgkins
lymphoma, Kaposi sarcoma, kidney, liver, lung, melanoma, multiple myeloma, Non-Hodgkins lymphoma,
oropharynx, ovary, pancreas, penis, prostate, stomach,
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testis, thyroid and vulva and vagina combined. Based
on 2017 data the 27 cancers chosen comprehended
1,339,737 of the 1,670,227 cancers reported to state cancer registries in that year or 80.21% of all non-melanoma
non-skin cancers reported. In addition total non-skin
cancer was also included in this list making 28 cancer
types in all.
19,877 age-adjusted cancer rates were retrieved from the
SEER*Stat State NPCR database. The total age-adjusted
number of cancers reviewed across the 28 cancer types
was 51,623,922 and the total aggregated population across
the period 2003–2017 was 124,896,418,350.
Other papers in this series consider these covariates as continuous [66] and categorical [67] covariates
respectively.

Fig. 1 Relationship of prostate and ovarian cancer incidence to cannabidiol exposure
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Specific cancer examples

Figure 1 shows the rates of two selected cancers, namely
(A) prostate cancer and (B) ovarian cancer against cannabidiol use. Panels (C) and (D) show these same plots as
log of the cancer rates. One notes that both prostate and
ovarian cancer rates are falling, as is cannabidiol exposure (Figs. 1 and 2). Fig. 2 shows a similar plot to Fig. 1 but
now representing the quintiles of cannabis exposure. The
steady shift of the regression line to the right indicates an
ordered relationship of these two tumours to cannabidiol
exposure quintile. These tumours are analyzed in greater
detail in the third paper in this series.
Prostate cancer

It is of interest to investigate some of the tumours most
significantly linked to cannabidiol exposure in further
detail. For this purpose prostate and ovarian cancer
have been chosen as illustrative rather than exhaustive
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examples of the way in which more detailed analyses may
be conducted upon these datasets.
We turn first to prostate cancer. The dramatically
declining rate of prostate cancer was noted in the first Figure in the first paper in this series. This is likely related to
the impact of the introduction of Prostate Specific Antigen (PSA) screening and its widespread application in
the community with a falling impact thereafter. Figure 3
(in the present paper) sets out the relationship of prostate
cancer to the exposure to various substances. One notes
an obviously positive relationship with tobacco, alcohol
and cocaine exposure and a negative relationship with
cannabis exposure.
Figure 4 shows the relationship of prostate cancer incidence to cannabinoid exposure. One notes that in most
cases cannabinoids are negatively associated with prostate cancer incidence with the notable exception of cannabidiol which is positively associated.

Fig. 2 Relationship of prostate and ovarian cancer incidence to cannabidiol exposure by cannabidiol exposure quintile
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Fig. 3 Prostate cancer rates by substance exposure

Fig. 4 Prostate cancer rates by estimated cannabinoid exposure
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Figure 5 sets out map-graphically the declining rate
of prostate cancer across USA over time. Figure 6 is a
bivariate map plot of the relationship between prostate
cancer incidence and cannabidiol exposure. The purple and pink tones show where both cannabidiol and
prostate cancer are high. One notes that as both fall
the map changes to green where both are low, with the
sole exception of Maine, Vermont and New Hampshire
which remain persistently elevated.
Supplementary Table 1 (Excel sheet “ST1 Pros lme”)
shows a series of increasingly inverse probability weighted
complex mixed effects models of the relationship of prostate cancer with various parameters. The relationship
with cannabis, THC and cannabigerol is noted to be
strongly negative. However the relationship with cannabidiol is highly significantly positive (β-estimate = 25.09,
95%C.I. 23.31, 26.87). The lower part of the Table presents final additive and interactive comprehensive models
including all drugs, ethnicity and income
Supplementary Table 2 (Excel sheet “ST1 Pros lme
Comp”) presents the results of an interactive cannabinoid
model. In this model terms including cannabidiol are
mostly negative
Supplementary Table 3 (Excel sheet “ST1 Pros SG”)
presents the results of comprehensive additive and interactive inverse probability weighted robust generalized
linear regression. In the additive model cannabidiol is
independently significant and the coefficient is positive.
The interactive model includes two terms where cannabidiol is positive and three where it is negative. The
net effect of cannabidiol, and indeed of all cannabinoids
in this interactive model, is strongly positive (by matrix
multiplication)

Fig. 5 Map-graph of prostate cancer rates across the USA
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Supplementary Table 4 (Excel sheet “ST1 Pros plm
Intro”) shows the results of panel regression for increasingly complex models. Cannabis terms are negative in
additive models. As shown in the last two models in this
table in both additive and interactive models cannabidiol
terms are positive
Supplementary Table 5 (Excel sheet “ST5 Pros plm Lag
Add”) presents a series of additive panel models lagged to
0, 2, 4, 6, and 8 years. One notes that at zero, 4 and 6 years
of lag cannabidiol is independently significant in these
models and its terms are positive. However at eight years
the term becomes negative. This indicates that the effects
of cannabidiol appears to have dissipated at eight years
which is to be expected of an environmental carcinogen
Supplementary Table 6 (Excel sheet “ST1 Pros plm
IR”) presents the results of lagging interactive models at
zero and two years. Due to the technical requirements
of panel models and the restrictions imposed by interactions on dimensionality constraints exhaustive analysis in
this format is not possible
Spatiotemporal models of prostate cancer

Figure 7 presents the geospatial relationships between
the various US states. As shown Hawaii and Alaska were
conceptually elided and edited onto the contiguous continental 48 US states to facilitate geospatial modelling.
Table 1 shows the introductory results of geospatial
modelling with these data. Cannabidiol is again found to
be strongly associated with prostatic cancer rates across
space and time together (β-estimate = 1.61 (C.I. 0.99,
2.23), P = 3.75 × 10− 7).
Table 2 presents the results of various temporally and
spatially lagged models. At 2 years lag cannabidiol is
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Fig. 6 Map-graph of bivariate distribution of prostate cancer and cannabidiol exposure across the USA. Drawn using colorplaner palette

independently significant and the coefficient is positive.
At six years lag cannabidiol is included in three terms
with an overall net positive effect.
Table 3 shows the final models from spatial and temporal lagging of various cannabinoids.
Various cannabinoids are shown to have both positive
and negative effects on the prostate cancer rate. For each
final model the net effect of cannabidiol is negative.
It is of interest to consider the modelled behaviour
of the predicted values as the percentile of cannabidiol
exposure increases. For the purposes of examining model
predictions the spatiotemporal model lagged to six years
shown in Table 2 was chosen. Figure 8 shows the behaviour of the fitted outcomes from the model as a function of

simultaneously increasing cannabidiol exposure. A line of
best fit (panel A), a cubic regression line (in panel B) and a.
general additive model (in panel C) was fitted to these
data. Table 4 presents the results of comparisons of the
various percentiles from this model. One notes that the
final column shows that the ratio of the various comparisons increases as a function of the increasing nature of
the curve and its various inflections.
Results of regression based upon the least squares
regression lines, polynomials and GAM fitted curves
is shown in Table 5. Anova tests demonstrated that the
cubic model was significantly better than the linear
model (Anova: F = 240.83, df = 2,97, P = 4.03 × 10− 39)
and that the GAM model was also better than the linear

Fig. 7 Geospatial links between various US states (A) edited and (B) Final. These links were used to form the sparse spatial weights matrices used in
the geospatial models for prostate and ovarian cancer
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Table 1 Prostatic Cancer – Introductory Space – Time Models
Parameter
Parameter

Model
Estimate (C.I.)

P

Coefficient Value

Cannabis Alone

S.D.

4.8855

spreml(Cancer Rate ~ Cannabis)

Log.Lik

− 2104.454

Cannabis

−3.34 (−4.54, − 2.15)

4.36e-08 phi

1.799117

0.0003

psi

0.662222

< 2.2e-16

rho
lambda

−0.809768

0.902303

THC Alone

S.D.

5.0538

spreml(Cancer Rate ~ THC exposure)

Log.Lik

− 2099.24

THC exposure

−2.06 (− 2.59, − 1.52)

P-Value

< 2.2e-16
< 2.2e-16

4.48e-14 phi

1.968582

0.0021

psi

0.626775

< 2.2e-16

rho
lambda

−0.782918

0.887035

< 2.2e-16
< 2.2e-16

Cannabigerol Alone

S.D.

1.0251

4.9450

spreml(Cancer Rate ~ Cannabigerol exposure)

Log.Lik

− 979.9955

− 2106.9850

Cannabigerol exposure

− 1.84 (− 2.58, − 1.1)

1.01e-06 phi

1.864451

0.0020

psi

0.655393

< 2.2e-16

rho
lambda

−0.80251

0.906276

Cannabidiol Alone

S.D.

5.1501

spreml(Cancer Rate ~ Cannabidiol exposure)

Log.Lik

− 2105.8960

Cannabidiol exposure

1.61 (0.99, 2.23)

< 2.2e-16
< 2.2e-16

3.75e-07 phi

2.064829

0.0016

psi

0.675325

< 2.2e-16

rho
lambda

−0.782638

0.897849

Additive Model - Drugs

S.D.

5.0551

spreml(Cancer Rate ~ Age + Cigarettes + AUD + Cannabis + Analgesics + Cocaine

Log.Lik

− 2088.4810

< 2.2e-16
< 2.2e-16

AUD

30.08 (3.65, 56.51)

0.02571

phi

2.045313

5.47e-05

Cannabis

−1.54 (−3, −0.08)

0.0384

psi

0.607328

< 2.2e-16

Age

−0.79 (− 1.13, − 0.46)

3.50e-06 rho

− 0.789941

lambda

0.878741

Interactive Model - Drugs

S.D.

5.0317

spreml(Cancer Rate ~ Age + Cigarettes * AUD * Cannabis + Analgesics + Cocaine

Log.Lik

Cannabis
Age

−1.81 (−3.22, − 0.39)

−0.9 (−1.21, − 0.59)

0.01231

phi

1.81e-08 psi
rho

− 2090.8060

2.018035

0.0030

0.61679

< 2.2e-16

−0.792062

lambda

0.88467

Interactive Model - Comprehensive

S.D.

4.8427

spreml(Cancer Rate ~ Age + Cigarettes * AUD * Cannabis + Analgesics + Cocaine + Income + Five Races)

Log.Lik

Age

Hispanic

−1 (−1.28, − 0.73)

−1.49 (− 2.56, − 0.42)

< 2.2e-16
< 2.2e-16

−2090.3930

< 2.2e-16
< 2.2e-16

4.04e-13 phi

1.751775

0.0003

0.006247 psi

0.63281

< 2.2e-16

rho
lambda

− 0.778829

0.88237

< 2.2e-16
< 2.2e-16

Interactive Cannabinoid Model - Comprehensive
spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Income + Five Races)
AUD

36.55 (9.15, 63.96)

0.0090

S.D.

5.1269

CBG

2.18 (0.2, 4.16)

0.0312

Log.Lik

THC: CBG: CBD

−5.19 (−8.32, − 2.06)

0.0012

phi

− 2079.543

2.152804

0.0015

Reece and Hulse Archives of Public Health

(2022) 80:101

Page 11 of 32

Table 1 (continued)
Parameter
Parameter
THC: CBD
THC: CBG
THC
Age

Model
Estimate (C.I.)
−17.59 (−28.21, −6.97)

P

Coefficient Value

P-Value

0.0012

psi

0.579133

< 2.2e-16

−21.24 (−33.23, −9.25)

0.0005

rho

−0.779342

< 2.2e-16

−0.84 (−1.24, − 0.43)

4.61e-05

−74.58 (−115.58, − 33.58) 0.0004

model (Anova: F = 245.26, df = 3,96, P = 1.25 × 10− 45).
These results show that the inflections in the curve are
highly statistically significant and this is consistent with
non-linearity of the effect, that is increasing effects at
higher cannabidiol concentrations and an increasing rate
of rise of the effect.
The applicable E-Values for these models are shown
in Table 6. In particular one notes that the minimum
E-Values for the cubic polynomial fit (5.59 × 1051 and
1.91 × 105) are much higher than those for the linear
model (1.79). As was noted above the polynomial is a
much better fit to the modelled data.
Ovarian cancer

We move next to consideration of ovarian carcinoma. As
shown in Fig. 9 ovarian cancer shows a positive relationship with all five substances examined except cannabis.
As seen in Fig. 10 ovarian carcinoma shows a positive
relationship with cannabidiol but a negative relationship
with other cannabinoids.
Figure 11 shows the falling rate of ovarian cancer across
USA over time. The bivariate relationship between cannabis use and ovarian cancer is shown map-graphically in
Fig. 12.
Mixed effects models for ovarian cancer are shown in
Supplementary Table 7 (Excel sheet “ST1 Ov lme”). Interestingly in additive models for drugs and for all covariates, cannabis is independently and positively predictive.
Supplementary Table 8 (Excel sheet “ST1 Ov lme
Cannbd”)presents the results of comprehensive additive
and interactive cannabinoid models. The three cannabinoids THC, cannabigerol and cannabidiol are noted to be
significant in both models. Cannabidiol is independently
significant with a positive coefficient in the interactive
model.
The positive relationship between cannabidiol and
ovarian cancer is confirmed by robust generalized linear
regression in Supplementary Table 9 (Excel sheet “ST1
Ov SG”).
In the robust comprehensive interactive models in Supplementary Table 10 (Excel sheet “ST1 Ov SG Cannbd”)

lambda

0.862257

< 2.2e-16

whilst the effects of cannabidiol are negative overall the
effects of rising cannabinoid percentiles is positive.
At panel regression cannabis is both independently
positive in its effects on ovarian cancer in additive models and has a positive effect overall in interactive models,
as shown in Supplementary Table 11 (Excel sheet “ST1
Ov plm Intro”).
Supplementary Table 12 (Excel sheet “ST1 Ov plm
Add”) shows a series of additive cannabinoid panel
models lagged to 0, 2, 4, 6 and 8 years. One notes that
at 2 and 8 years cannabidiol has a positive and independently highly significant effect (β-estimate = 1.84 (1.44,
2.23), P = 1.2 × 10− 19 and β-estimate = 8.51 (6.96, 10.07),
P = 8.06 × 10− 27 respectively)
In interactive cannabinoid panel models cannabidiol
is again positively related to ovarian cancer rates at both
zero and two years lag (Supplementary Table 13, Excel
sheet “ST1 Ov plm IR”)).
Table 7 shows the results of introductory temporospatial modelling. The effect of cannabidiol alone is
again noted to be positive (β-estimate = 0.36 (0.3, 0.42),
P < 2.2 × 10− 16).
As shown in Table 8 cannabis exposure is negatively
associated with ovarian cancer.
Table 9 presents the results of spatial models lagged
to 2, 4 and 6 years. In the first two models cannabinoids
have a negative effect on ovarian cancer incidence. When
lagged to 6 years cannabinoids in general, and cannabidiol in particular, has an overwhelmingly positive effect on
ovarian cancer incidence.
Spatiotemporally lagged models are presented in
Table 10. The effect of cannabinoids in these models is
negative.
It is of interest to consider the effect of spatiotemporal modelling for ovarian carcinoma. Fig. 13 presents the
results of predictive model output from the interactive
spatial model at 6 lags shown in Table 9 of cannabinoids
and ovarian cancer with 101 increasing percentiles of
cannabidiol exposure. Again a sigmoidal curve shape is
noted. Linear, cubic, quintic and GAM functions are fitted. Table 11 presents the results of the comparisons of
the model values at varying cannabinoid percentiles and
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Table 2 Prostatic Cancer – Lagged Space – Time Models
Lagged Variables

Parameter
Parameter

Model
estimate (C.I.)

P

Coefficient

Value

P-Value

LAGGING WITH CANNABINOIDS
Comprehensive Interactive Model
- 2 Temporal Lags
Temporal Lags:
THC, 2

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)
Cocaine

80.28 (15.7, 144.86)

0.0148

S.D.

5.2086

CBD

5.95 (0.76, 11.15)

0.0247

Log.Lik

− 1772.068

Cannabidiol, 2

Analgesics

59.62 (6.42, 112.81)

0.0280

phi

2.689466

0.0004161

Cannabigerol, 2

Income

3.89 (0.36, 7.43)

0.0308

psi

0.583621

< 2.2e-16

CBG
Cigarettes: CBG
Cigarettes
Cigarettes: CBD
Cigarettes: CBG: CBD
Age

−5.07 (−9.71, − 0.44)

−62.38 (−108.32, −16.43)

− 282.27 (− 484.13, −80.41)

−88.44 (−137.35, −39.53)

−20.64 (− 31.36, −9.92)

−0.72 (−1.09, − 0.35)

0.0318

rho

0.0078

lambda

− 0.826646

0.84905

< 2.2e-16
< 2.2e-16

0.0061
0.0004
0.0002
0.0001

Comprehensive Interactive Model - 4 Temporal Lags

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)
Cocaine

0.0006

0.0006

S.D.

4.7498

THC, 4

Hispanic

0.0012

0.0012

Log.Lik

Cannabidiol, 4

Age

2.18e-10

2.18e-10

phi

− 1505.899

2.091523

psi

0.652059

< 2.2e-16

rho

−0.829187

< 2.2e-16

Temporal Lags:

Cannabigerol, 4

lambda

0.876342

0.0004814

< 2.2e-16

Comprehensive Interactive Model - 6 Temporal Lags
Temporal Lags:
THC, 6

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)
Cigarettes: THC: CBG

24.04 (14.72, 33.36)

4.29e-07

S.D.

5.1497

Cigarettes: CBG

334.94 (176.94, 492.95)

3.26e-05

Log.Lik

− 1218.3530

Cannabidiol, 6

Cigarettes

1080.16 (552.4, 1607.92)

6.03e-05

phi

2.710614

3.11e-05

Cannabigerol, 6

Cigarettes: CBG: CBD

49.06 (17.39, 80.73)

0.0024

psi

0.617539

< 2.2e-16

Cigarettes: CBD

150.69 (45.25, 256.13)

0.0051

rho

Age

− 0.63 (−1.09, − 0.18)

0.0067

lambda

CBG
THC
THC: CBD

−38.43 (−55.72, −21.13)

−53.27 (−77, −29.55)

−20.22 (− 28, − 12.44)

−0.722522

0.822562

< 2.2e-16
< 2.2e-16

1.33e-05
1.07e-05
3.49e-07

Comprehensive Interactive Model - 1 Spatial Lag
Spatial Lags:
THC, 1

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)
Cigarettes: THC: CBD

Cigarettes: THC: CBG: CBD

Cannabidiol, 1

Cigarettes: THC

Cannabigerol, 1

Cigarettes: THC: CBG
Age

−128.412 (− 202.52, − 54.31)

−38.166 (− 59.63, − 16.7)

−517.602 (− 800.36, − 234.85)

−151.094 (− 232.66, −69.53)

− 0.949 (−1.34, − 0.56)

an increasing effect of rising cannabidiol concentrations
is noted. The results of model regression are shown in
Table 12.
Model comparison with anova tests confirm that the
cubic fit is better than the linear fit (Anova: F = 118.17,

0.0006

S.D.

5.1497

0.0070

Log.Lik

− 2081.4700

0.0053

phi

2.09673

3.96e-06

0.0034

psi

0.593689

< 2.2e-16

4.3e-05

rho
lambda

− 0.765839

0.867413

< 2.2e-16
< 2.2e-16

df = 2,97, P = 2.89 × 10− 27), the quintic fit is better than the cubic fit (Anova: F = 233.77, df = 2,95,
P = 3.44 × 10− 38), and the GAM model is better than
both the linear fit (Anova: F = 177.85, df = 7.810, 914.19,
P = 1.81 × 10− 52) and the cubic fit (Anova: F = 58.441,
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Table 3 Prostatic Cancer – Spatially and Temporally Lagged Space – Time Cannabinoid Models
Lagging

Parameter

Lagged Variables

Parameter

Model
estimate (C.I.)

P

Coefficient

Value

P-Value

Spatiotemporal Lags
Comprehensive Interactive Model - 1 Spatial & 2 Temporal Lags
THC Temporally Lagged
spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)
Income

6.59 (3.22, 9.96)

0.0001

S.D.

4.6652

THC, 1

Cocaine

1.82 (0.58, 3.06)

0.0039

Log.Lik

Cannabigerol, 1

Analgesics

2.54 (0.16, 4.92)

0.0365

phi

−1759.5510
1.9006

0.0003446

Cannabidiol, 1

Hispanic

0.0139

psi

0.5811

< 2.2e-16

Temporal:

Cigarettes: THC: CBD

−1.74 (−3.13, − 0.35)

0.0004

rho

Age

0.0004

lambda

AUD,2

Cigarettes: THC

−0.82 (−1.27, − 0.37)

− 0.8096

< 2.2e-16

Cigarettes,2

−128.33 (− 199.73, −56.93)
−513.27 (− 786.94, − 239.59)

0.0002

Spatial:

THC, 2

Cigarettes: THC: CBG: CBD

Analgesics, 2

Cigarettes: THC: CBG

Cocaine, 2

THC
Comprehensive Interactive Model - 1
Spatial & 2 Temporal Lags

−39.99 (− 60.98, −19)

−158.61 (− 238.74, − 78.49)

−2.9 (−3.93, − 1.87)

0.8158

< 2.2e-16

0.0002
0.0001
3.11e-08

Cannabidiol Temporally Lagged
spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)
CBD

2.08 (1.19, 2.98)

5.20e-06

S.D.

4.7079

THC, 1

Cocaine

2.56 (1.3, 3.81)

6.75e-05

Log.Lik

Cannabigerol, 1

Income

5.5 (2.26, 8.75)

0.0009

phi

− 1758.7820
5.3487

1.83e-08

Cannabidiol, 1

CBD.Spatial

1.06 (0.03, 2.1)

0.0442

psi

0.6391

< 2.2e-16

Temporal:

AIAN

0.0294

rho

THC: CBG: CBD

0.0257

lambda

−0.7110

5.65e-16

Cigarettes,2

−32.1 (−60.98, −3.21)

AUD,2

Hispanic

−2.33 (−3.69, −0.97)

0.0008

Spatial:

Cannabidiol, 2

Cigarettes: THC: CBD

Analgesics, 2

Cigarettes: THC: CBG: CBD

Cocaine, 2

Cigarettes: THC
Cigarettes: THC: CBG
Age

−0.43 (− 0.81, − 0.05)

−163.72 (− 246.95, −80.48)

−48.79 (−73.06, − 24.51)

0.0001
5.39e-05

−1.18 (− 1.59, − 0.76)

2.36e-08

2.17e-05

Spatial:

Comprehensive Interactive Model - 1 Spatial & 4 Temporal Lags

THC, 1

THC Temporally Lagged

Cannabigerol, 1

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)

Cannabidiol, 1

< 2.2e-16

8.17e-05

−651.36 (−967.53, − 335.2)

−199.58 (− 291.7, − 107.47)

0.6854

THC

642.76 (165.3, 1120.23)

0.0083

S.D.

18.5723

Temporal:

CBG: THC

181.1 (41.49, 320.71)

0.0110

Log.Lik

Cigarettes,4

CBD: THC

146.56 (25.64, 267.49)

0.0175

phi

− 2045.3050
2.2917

0.0009418

AUD,4

CBG: CBD: THC

41.24 (5.57, 76.9)

0.0235

psi

0.6228

< 2.2e-16

THC, 4

Cocaine

1.42 (0.18, 2.65)

0.0247

rho

< 2.2e-16

Analgesics, 4

Cigarettes: CBG: CBD: THC

0.0090

lambda

Cocaine, 4

Cigarettes: CBD: THC

−192.44 (− 336.83, −48.04)

−0.8426

−2 (−3.43, −0.58)

0.0060

− 3015.28 (− 4971.81, − 1058.74)

0.0025

Hispanic
Cigarettes: CBG: THC
Cigarettes: THC
Age

− 694.28 (−1189.26, − 199.3)

0.0060

− 837.5 (− 1403.64, − 271.36)

0.0037

−1.06 (− 1.48, − 0.64)

7.82e-07

0.8542

Spatial:

Comprehensive Interactive Model - 1 Spatial & 4 Temporal Lags

THC, 1

Cannabidiol Temporally Lagged

Cannabigerol, 1

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)

Cannabidiol, 1

Cocaine

2.34 (1.21, 3.46)

4.53e-05

S.D.

4.7813

< 2.2e-16
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Table 3 (continued)
Lagging

Parameter

Model

Lagged Variables

Parameter

estimate (C.I.)

P

Coefficient

Value

Temporal:

THC: CBG

19.63 (6.78, 32.48)

0.0028

Log.Lik

Cigarettes,4

THC

64.38 (22.13, 106.64)

0.0028

phi

− 1492.4380
2.2091

0.0002842

AUD,4

CBD

0.0374

psi

0.5981

< 2.2e-16

Cannabidiol, 4

Cigarettes: THC: CBG: CBD: CBD.Spatial

−1.05 (−2.04, −0.06)

0.0272

rho

Cigarettes: THC: CBG

0.0018

lambda

Cocaine, 4

Hispanic

−83.75 (− 136.43, −31.07)

−0.8249

< 2.2e-16

Analgesics, 4

−0.41 (− 0.78, − 0.05)
−2.26 (−3.63, − 0.9)

0.0012

−303.31 (−480.04, −126.57)

0.0008

−1.06 (− 1.48, −0.64)

7.18e-07

Cigarettes: THC
Age

0.8468

P-Value

< 2.2e-16

Fig. 8 Modelled scaled output values from geospatial models of a comprehensive interactive prostate cancer model lagged to six years

Table 4 Prostate Cancer - Percentile Rank Comparisons
Percentiles

Difference Ratio

Low Percentile
Rank

High Percentile
Value

Rank

Value

10th Percentile 42.5469 90th Percentile 74.8319 32.2850

1.7588

5th Percentile

39.4475 95th Percentile 78.6431 39.1956

1.9936

1st Percentile

34.3401 99th Percentile 82.6379 48.2978

2.4065

df = 5.81, 91.19, P = 5.91 × 10− 29). These results show that
the inflections in the curves are statistically highly significant and explain the increasing acceleration of the effect
of cannabidiol exposure on ovarian cancer incidence as
the cannabidiol exposure rises, indicating a strong power
function effect with rising dose.

Table 13 presents the E-Values applicable to the linear,
cubic and quintic fitted functions for cannabidiol exposure, all of which are highly signifcant. Minimum E-Values range up to 1.92 × 10− 125 in this table for the quintic
function.

Discussion
Main results

As it was demonstrated in the first and second papers
in this series [66, 67] that prostate and ovarian cancers
were closely associated with cannabidiol exposure these
tumours were explored in more analytical detail by way
of the present exemplary analyses. The strong bivariate relationships observed were robust to adjustment in
comprehensive interactive inverse probability weighted
mixed effects, robust generalized and panel models
and also in space-time analyses. In selected geospatial
models for these two tumours polynomial minimum
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Table 5 Prostate Cancer – Predictive Regression Model Summaries
Linear Models
Parameter

Model

Term

Estimate (C.I.)

P_Value

Adj.R.Squared Standard t-Value
Deviation

P-Value

0.95 (0.92, 0.97)

2.52E-87

0.9811

3.8586

5185.354

2.52E-87

0.9943

2.1028

5898.511

1.31E-109

Akaike
Information
Crierion

Bayesian
Information
Criterion

297.5044

325.7959

Linear Model
Percentile
Cubic Polynomial Model
First Order Percentile

277.86 (273.73, 281.98)

2.58E-111

Second Order Percentile

−10.41 (− 14.53, − 6.28)

3.15E-06

Third Order Percentile

30.61 (26.49, 34.73)

3.91E-26

P-Value

GAM Model
Parameter

Model

Term

Estimated
Degress of
Freedom

Residual
Degrees of
Freedom

Statistic

Log.Likelihood

Smoothened Percentile

8.8184

8.9902

8777.838 < 2.2E-320 − 137.9338

Table 6 Prostate Cancer – E-Values of Predictive Regression Models
term

Estimate

Standard Error

Stanhdard
Deviation

Relative Risk

E-Values

0.8193

0.0162

4.7448

1.25 (1.24, 1.26)

1.81, 1.79

First Order Percentile

277.8563

2.1028

2.1028

1.66E+ 52 (2.79E+ 51, 9.84E+ 52)

3.31E+ 52, 5.59E+ 51

Third Order Percentile

30.6074

2.1028

2.1028

5.65E+ 05 (9.53E+ 04, 3.35E+ 06)

1.13E+ 06, 1.91E+ 05

Linear Model
Percentile
Cubic Polynomial Model

E-Values ranged up to 5.59 × 1059 and 1.92 × 10125.
Moreover the dose-response relationships between
rising modelled cannabidiol exposure and increasing
cancer incidence was strongly non-linear with general
additive model spline curves fitting the predicted data
much better than linear models at significance levels
of 1.25 × 10− 45 and 1.81 × 10− 52 respectively. This was
strong evidence of a supra-linear sigmoidal powerfunction relationship with cancerogenesis.
We are very concerned at the supra-linear sigmoidal
shape of the cannabinoid dose-oncogenesis response
curve demonstrated in both tumours examined by predictive spatiotemporal modelling. Its direct corollary
is that rising levels of cannabinoid exposure will be
met by an inordinate increase in carcinogenesis. From
the findings with AML and other pediatric cannabisrelated tumours [11, 17–19, 96–99] real concerns exist
that this may lead to a multigenerational epidemic of
cancer. This view is closely concordant with a recent
report describing cannabis exposure as a primary
driver of USA pediatric cancers [100] and of the commonest cancer of childhood acute lymphoid leukaemia

[28]. From the very clear findings with testicular cancer
it would appear that the usual course of oncogenesis
may be greatly accelerated [101].
The strong bivariate relationships reported herein
and in the accompanying reports [66, 67] demonstrate
that the cannabinoid-cancer relationships are robust
to adjustment, fulfil quantitative epidemiological criteria for causality, and for prostate and ovarian cancer
demonstrate a supra-linear sigmoidal dose-response
relationship with carcinogenic outcomes so that rising
doses of cannabinoid exposure generate disproportionate tumorigenic outcomes. Rather than prostate and
ovarian cancer being outliers, our unpublished analyses to date show that the observations made on these
cancers, particularly in relation to supra-linear sigmoidal dose-response exposure-oncogenic outcome relationships can also be found for many other tumours
(manuscript in preparation). In this context the wide
distribution and free availability of many cannabinoids
including cannabidiol is of particular concern not only
for the effect on the users, but as shown by ALL which
is primarily a paediatric tumour [28], on subsequent
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Fig. 9 Relationship of ovarian cancer to various substance exposures

Fig. 10 Relationship of various estimated cannabinoid exposures to ovarian cancer
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Fig. 11 Map-graph of ovarian cancer rates across USA over time

Fig. 12 Bivariate map-graph of the relationship between cannabidiol use and the ovarian cancer across USA over time

generations who are exposed indirectly through parental access and presumably via gametotoxic, genotoxic
and epigenotoxic pathways.
Prostate cancer summary

Terms including THC, cannabigerol and cannabidiol
are significant in final comprehensive interactive mixed
effects models (Supplementary Tables 1 and 2). Cannabidiol is independently significant in comprehensive
additive robust generalized linear model (Supplementary
Table 3). In an interactive comprehensive robust generalized linear model the effects of cannabinoids THC,

cannabigerol and cannabidiol were overwhelmingly positive (Supplementary Table 3).
In a series of lagged additive panel models cannabidiol
was independently significant with positive coefficients
at zero, four and six years (Supplementary Table 5). In
a series of comprehensive interactive panel models cannabidiol was independently significant at zero and two
years lag (Supplementary Tables 5 and 6).
Cannabidiol by itself was geospatiotemporally positively associated with prostate cancer rates (Table 1). In
interactive geospatiotemporal models CBD was significantly positively associated with prostate cancer rates at
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Table 7 Ovarian Cancer – Introductory Space-Time Regression
Parameter
Parameter

Model
estimate (C.I.)

P

Coefficient

Value

Cannabis Alone

S.D.

0.6119

spreml(Cancer Rate ~ Cannabis)

Log.Lik

− 719.3662

Cannabis

−0.46 (− 0.57, − 0.35)

< 2.2e-16

phi
rho
lambda

THC Alone
spreml(Cancer Rate ~ THC exposure)
THC exposure

−0.36 (− 0.41, − 0.31)

< 2.2e-16

Cannabigerol exposure

−699.7751

S.D.
Log.Lik
−0.43 (−0.5, − 0.35)

< 2.2e-16

Cannabidiol exposure

< 2.2e-16

5.09e-05

−0.687793

< 2.2e-16

0.7014

< 2.2e-16

0.6175
− 709.6908

5.16e-05

rho

−0.738106

< 2.2e-16

Log.Lik
0.36 (0.3, 0.42)

0.534787

0.557597

S.D.

spreml(Cancer Rate ~ Cannabidiol exposure)

< 2.2e-16

phi
lambda

Cannabidiol Alone

< 2.2e-16

0.803723

Log.Lik

lambda
spreml(Cancer Rate ~ Cannabigerol exposure)

5.73e-05

−0.786241
0.6212

rho

Cannabigerol Alone

0.578764

S.D.
phi

P-Value

0.754643

< 2.2e-16

0.6246
−709.5827

phi

0.58377

4.66e-05

rho

−0.71922

< 2.2e-16

lambda

0.746991

< 2.2e-16

Additive Model - Drugs
spreml(Cancer Rate ~ Age + Cigarettes + AUD + Cannabis + Analgesics + Cocaine
Analgesics

6.5 (0.56, 12.43)

0.0319

S.D.

0.6667

Log.Lik

− 682.9304

AUD

4.82 (1.04, 8.59)

0.0123

phi

0.836607

3.34e-05

Cigarettes

3.97 (2.36, 5.57)

1.27e-06

rho

< 2.2e-16

Age

−0.06 (− 0.1, − 0.03)

0.0005

lambda

−0.690814

S.D.

0.6630

0.0104

Log.Lik

− 681.5923

Interactive Model - Drugs

spreml(Cancer Rate ~ Age + Cigarettes * AUD * Cannabis + Analgesics + Cocaine
Cigarettes

2.73 (0.64, 4.83)

0.637209

< 2.2e-16

Analgesics

6.83 (0.89, 12.76)

0.0243

phi

0.810219

4.21e-05

Age

−0.05 (−0.09, − 0.02)

0.0055

rho

< 2.2e-16

0.0024

lambda

−0.683232

Cigarettes: Cannabis: AUD
Interactive Model - Comprehensive

−6.85 (−11.26, −2.43)

spreml(Cancer Rate ~ Age + Cigarettes * AUD * Cannabis + Analgesics + Cocaine + Income + Five Races)

0.631604

Cigarettes

3.9 (2.04, 5.77)

4.19e-05

S.D.

0.6762

Analgesics

6.42 (0.38, 12.45)

0.0373

Log.Lik

−674.869

African
Income
AIAN
Age
Interactive Cannabinoid Model - Comprehensive

−0.14 (− 0.24, − 0.03)

−0.62 (−1.07, − 0.16)

−5.52 (−9.19, − 1.86)

−0.07 (− 0.11, − 0.03)

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Income + Five Races)

< 2.2e-16

0.0095

phi

3.3102

0.003983

0.0083

rho

< 2.2e-16

0.0032

lambda

− 0.6737

0.7279

< 2.2e-16

0.0005

Cigarettes

3.58 (1.58, 5.58)

0.0005

S.D.

0.6448

CBG

0.69 (0.32, 1.07)

0.0003

Log.Lik

−672.8832

Hispanic

0.15 (0.01, 0.29)

0.0303

phi

0.686632

4.17e-05

Cocaine

−8.04 (−15.8, −0.28)

0.0422

rho

1.43e-15

0.0256

lambda

−0.640042

AIAN
Income
THC

−3.78 (−7.09, −0.46)

−0.73 (−1.21, − 0.26)

−0.72 (−1, − 0.44)

0.0023
3.87e-07

0.597138

< 2.2e-16
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Table 8 Ovarian Cancer – Lagged Space-Time Regression
Lagged Variables Parameter
Parameter

Model
Estimate (C.I.)

P

Coefficient Value

P-Value

LAGGING WITH CANNABIS
Temporal Lagging
Comprehensive Interactive Model - 2 Temporal Lags
Cigarettes, 2

spreml(Cancer Rate ~ Age + Cigarettes * AUD * Cannabis + Analgesics + Cocaine + Income + Five Races)
Caucasian

AUD, 2

AIAN

Cannabis, 2

African

Analgesics, 2

Income

Cocaine, 2

Cannabis
Comprehensive Interactive Model - 4 Temporal Lags

Cigarettes, 4

−0.78 (− 1.49, − 0.07) 0.0306

S.D.

0.6405

Log.Lik

−0.18 (− 0.29, − 0.08) 0.0006

phi

− 569.0211

−5.31 (− 8.92, − 1.71) 0.0039

−0.92 (−1.32, − 0.53) 4.50e-06 rho

−0.5 (− 0.69, − 0.31)

spreml(Cancer Rate ~ Age + Cigarettes * AUD * Cannabis + Analgesics + Cocaine + Income + Five Races)

2.71e-07 lambda

0.8173

8.97e-05

− 0.6447

7.27e-16

0.6346

S.D.

0.5950

Log.Lik

− 473.9722

< 2.2e-16

Cocaine

13.5 (5.36, 21.65)

0.0012

phi

0.5570

0.0002

AUD, 4

Cigarettes

2.34 (0.29, 4.4)

0.0257

rho

8.03e-08

Cannabis, 4

Cannabis

−0.37 (− 0.57, − 0.17) 0.0003

−0.5503

Analgesics, 4

lambda

0.6351

< 2.2e-16

Cocaine, 4
Spatial Lagging
Comprehensive Interactive Model - 1 Spatial Lag
Cannabis, 1

spreml(Cancer Rate ~ Age + Cigarettes * AUD * Cannabis + Analgesics + Cocaine + Income + Five Races)
Cigarettes: Cannabis: AUD:

2.87 (1.57, 4.17)

1.44e-05 S.D.

0.6618

AIAN

−3.74 (−7.14, −0.33)

0.0313

−674.5209

Cannabis
Age
Cannabis
Income
Spatiotemporal Lagging

−0.45 (− 0.82, − 0.08) 0.0183

−0.06 (− 0.11, − 0.02) 0.0042

−0.16 (− 0.26, − 0.06) 0.0017

−0.7 (−1.11, − 0.29)

Log.Lik
phi

0.8060

3.02e-05

rho

−0.6641

< 2.2e-16

lambda

0.6062

Spatial Lags:

Comprehensive Interactive Model - 1 Spatial & 2 Temporal Lags

Cannabis, 1

In this model Cannabis was considered as both a spatially and temporally lagged variable

Temporal Lags:

spreml(Cancer Rate ~ Age + Cigarettes * AUD * Cannabis + Analgesics + Cocaine + Income + Five Races)

Cigarettes, 2

Cigarettes

3.9 (2.15, 5.64)

AUD, 2

White

Log.Lik

Cannabis, 2

AIAN

−0.97 (−1.68, − 0.25) 0.0082

0.0011

phi

Analgesics, 2

African

−0.2 (− 0.31, − 0.1)

0.0002

rho

−6.01 (−9.63, −2.39)

1.21e-05 S.D.

−0.52 (− 0.71, − 0.32) 2.58e-07 lambda

18.7670
− 2419.9740
0.7901

0.0001

− 0.6287

2.11e-14

Cocaine, 2

Cannabis

Spatial Lags:

Comprehensive Interactive Model - 1 Spatial & 4 Temporal Lags

Cannabis, 1

In this model Cannabis was considered as both a spatially and temporally lagged variable

S.D.

0.5877

Temporal Lags:

spreml(Cancer Rate ~ Age + Cigarettes * AUD * Cannabis + Analgesics + Cocaine + Income + Five Races)

Log.Lik

−474.4161

Cigarettes, 4

< 2.2e-16

0.0008

0.6229

< 2.2e-16

Cocaine

14.43 (6.66, 22.21)

0.0003

phi

0.5226

0.0001

AUD, 4

Income

0.0492

rho

Cannabis

0.0050

lambda

−0.5685

1.27e-08

Cannabis, 4

−0.47 (−0.94, 0)

Analgesics, 4

−0.32 (− 0.54, − 0.1)

0.6437

< 2.2e-16

Cocaine, 4

2 and 6 lags (Table 2). In an interactive spatiotemporal
model with spatial and temporal lagging where cannabidiol was temporally and spatially lagged, cannabidiol

was independently significantly associated with prostate
cancer rates (Table 3). The cannabinoids THC, cannabigerol and cannabidiol are independently significantly
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Table 9 Ovarian Cancer – Lagged Cannabinoid Space-Time Regression
Lagged Variables

Parameter
Parameter

Model
estimate (C.I.)

P

Coefficient

Value

Temporal Lags:

LAGGING WITH CANNABINOIDS

THC, 2

Comprehensive Interactive Model - 2 Temporal Lags

Cannabidiol, 2

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)

Cannabigerol, 2
Cigarettes, 2

Income

THC

AUD, 2

− 0.57 (−1.03, − 0.11)

−0.32 (− 0.42, − 0.23)

0.0157

S.D.

0.6168

1.64e-10

Log.Lik

− 574.7914

phi

Analgesics, 2

rho

Cocaine, 2

lambda

0.587232

5.71e-05

−0.581409

5.83e-10

0.628577

Temporal Lags:

Comprehensive Interactive Model - 4 Temporal Lags

THC, 4

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)

Cannabidiol, 4

Cocaine

9.14 (0.28, 18)

0.0433

S.D.

0.3489

Cannabigerol, 4

Cigarettes: THC: CBG

0.0021

Log.Lik

Cigarettes, 4

Cigarettes: THC

−1.16 (−1.91, −0.42)

− 460.3743

AUD, 4

−6.09 (−8.87, −3.31)

1.79e-05

Analgesics, 4

P-Value

< 2.2e-16

phi

0.50581

9.48e-05

rho

−0.47394

3.27e-05

lambda

0.526539

7.87e-14

Cocaine, 4
Comprehensive Interactive Model - 6 Temporal Lags
Temporal Lags:
THC, 6
Cannabidiol, 6

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)
Cigarettes: THC: CBD

1.93 (1.07, 2.78)

9.96e-06

S.D.

0.5552

White

1.31 (0.53, 2.09)

0.0010

Log.Lik

−359.3580

Cannabigerol, 6

Hispanic

0.24 (0.09, 0.39)

0.0016

phi

0.311493

0.0009978

Cigarettes, 6

Cocaine

16.36 (5.53, 27.19)

0.0031

rho

0.0821654

lambda

−0.25786

AUD, 6

THC: CBG: CBD

0.07 (0.02, 0.12)

0.0049

Analgesics, 6

AUD

0.0074

Cocaine, 6

Cigarettes: CBG: CBD

−6.67 (−11.56, −1.79)

−0.24 (−0.4, − 0.09)

associated with prostate cancer rates in comprehensive
interactive space-time models (Tables 2 and 3).
Examining the space-time model lagged to 6 years one
notes that the predictive values for increasing percentiles
of cannabidiol exposure show a strong positive upward
trend, and that the curve has obvious inflections making
the cubic and GAM fits much better fits to the predicted
model values. Inflections and supra-linear sigmoidality
are highly statistically significant.
Hence in all pseudorandomized and geospatial models
cannabinoids and cannabidiol are significantly associated
with prostate cancer including positive coefficients in
final comprehensive interactive models.
Ovarian cancer summary

Cannabinoids are predictive in both additive and comprehensive mixed effects models (Supplementary Table 7).
Cannabidiol is independently positively predictive in an
interactive mixed effects model (Supplementary Table 8).
In a robust generalized linear comprehensive interactive

0.40592

8.75e-05

0.0025

model cannabidiol is independently positively significant
(Supplementary Table 10).
At 2 and 8 lags cannabidiol is independently and positively significant in lagged additive panel models (Supplementary Table 12). At zero and 2 years of lag terms
including cannabidiol are positively significant in interactive panel models (Supplementary Table 13). In spacetime models cannabidiol considered alone is positively
significant (Table 7). Terms including cannabidiol are significant and positive at 6 lags (Table 8).
It is possible to consider ovarian cancer as a lagged
function of increasing cannabidiol and cannabinoid concentrations. Inflections in the dose-response relationship
curve strongly indicate that the relationship is supralinear, sigmoidal and a non-linear power function of the
percentile cannabidiol exposure.
Hence in all models cannabinoids and cannabidiol are
significantly associated with ovarian cancer including
positive coefficients in final comprehensive interactive
models.
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Table 10 Ovarian Cancer – Spatially and Temporally Lagged Space-Time Regression
Lagged Variables Parameter
Parameter

Model
Estimate (C.I.)

P

Coefficient Value

P-Value

Comprehensive Interactive Model - 1 Spatial Lag
spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)

Spatial Lags:

White

47.91 (20.68, 75.13)

0.0006

S.D.

0.4125

THC, 1

Age

0.0070

Log.Lik

Cannabidiol, 1

Cannabigerol: Cannabidiol

−2 (−3.46, − 0.55)

0.0053

phi

−672.3628

Cannabigerol, 1

THC: Cannabigerol

−6.3 (− 10.51, − 2.08)

0.0034

rho

THC

− 0.94 (− 1.59, − 0.28)

−31.25 (−46.22, − 16.28) 4.3e-05

Spatial:

Comprehensive Interactive Model - 1 Spatial & 1 Temporal Lags

THC, 1

THC Lagged both Temporally and Spatially

Cannabigerol, 1

lambda

4.2682

1.83e-08

− 0.5883

2.59e-12

0.6520

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)

Cannabidiol, 1

Cigarettes

6.17 (3.38, 8.97)

1.54e-05 S.D.

0.6109

Temporal:

Hispanic

0.16 (0.03, 0.29)

0.0162

Log.Lik

Cigarettes,1

African

0.0201

phi

−621.5385

AUD,1

AIAN

−0.11 (−0.21, − 0.02)

0.0018

rho

THC, 1

Cigarettes: CBG: CBD

−5.2 (−8.47, −1.94)

0.0013

lambda

Analgesics, 1

Income

−0.28 (− 0.45, − 0.11)

0.0006

Cocaine, 1

THC

−0.83 (−1.3, − 0.36)

−0.22 (− 0.32, − 0.12)

1.07e-05

Spatial:

Comprehensive Interactive Model - 1 Spatial & 2 Temporal Lags

THC, 1

THC Lagged both Temporally and Spatially

Cannabigerol, 1

< 2.2e-16

0.5509

8.38e-05

−0.6617

9.76e-16

0.6109

< 2.2e-16

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)

Cannabidiol, 1

CBG

0.77 (0.38, 1.16)

9.90e-05 S.D.

0.6190

Temporal:

Income

0.0017

Cigarettes,2

THC

−0.76 (−1.23, − 0.29)

−567.1623

AUD,2

THC

−0.33 (− 0.48, − 0.17)

2.67e-05 rho

THC, 2

−0.52 (− 0.78, − 0.26)

Log.Lik

7.78e-05 phi
lambda

0.5898

−0.5512

0.5790

8.16e-05
2.44e-08
< 2.2e-16

Analgesics, 2
Cocaine, 2
Spatial:

Comprehensive Interactive Model - 1 Spatial & 4
Temporal Lags

THC, 1

THC Lagged both Temporally and Spatially

Cannabigerol, 1

spreml(Cancer Rate ~ Age + Cigarettes * THC * CBG * CBD + AUD + Analgesics + Cocaine + Income + Five Races)

Cannabidiol, 1

CBG

0.76 (0.22, 1.31)

0.0061

S.D.

0.5875

Temporal:

Cocaine

0.25 (0.09, 0.42)

0.0023

Log.Lik

Cigarettes,4

THC: CBG

0.2 (0.05, 0.35)

0.0073

phi

− 452.9861

AUD,4

Cigarettes: THC: CBG: THC

0.0482

rho

THC, 4

Cigarettes: THC: CBG: CBD: THC

−4.21 (−8.39, −0.03)

0.0261

lambda

Analgesics, 4

THC

−0.47 (− 0.62, − 0.33)

9.73e-11

Cocaine, 4

Interpretation
Causal assignment

E-values have been used extensively in the present
report. In the literature E-Values greater than 1.25 are
said to be linked with causality [91]. It is worth noting
that the minimum E-Value for the association between
tobacco smoke and lung cancer is 9. This places the
greatly elevated E-Values highlighted in this report in

−1.24 (−2.34, −0.15)

0.4665

0.0001169

−0.4140

0.0006749

0.4449

7.33e-08

a proper context. The methodology employed here has
also been validated en passant in that many tobaccorelated cancers including lung, colorectum, all cancer, vulva and vagina, penis, bladder, oropharynx and
esophagus, were correctly identified as such by the
methodology adopted. Further age was correctly identified as a major risk factor for prostate cancer in the
regression models.
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Fig. 13 Modelled scaled output values from geospatial models of a comprehensive interactive ovarian cancer model lagged to six years

Our regression modelling used inverse probability
weighting in all mixed effects, robust generalized and
panel regression models. This is the method of choice for
application in observational studies to even out an exposure of interest across experimental groups and create a
pseudo-randomized cohort from which causal inferences
can properly be drawn.

Mechanisms

Central to any causal consideration of the relationship
between cannabinoid exposure and carcinogenicity is
the pivotal issue of the biological pathways by which cannabinoids might exert any oncogenic activities. This section is intended to be read alongside similar mechanistic
discussions in the first and second papers in this series.
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Table 11 Ovarian Cancer – Predicted Model Percentile Values
Percentiles

Difference Ratio

Low Percentile
Rank

High Percentile
Value

Rank

Value

10th Percentile 5.4089 90th Percentile 6.6647 1.2558

1.2322

5th Percentile

5.2884 95th Percentile 6.8129 1.5245

1.2883

1st Percentile

5.0897 99th Percentile 6.9683 1.8786

1.3691

Rather than addressing prostatic and ovarian carcinogenesis specifically the present mechanistic discussion will
focus on general oncogenic activities of cannabinoids in
many tissues overall, and will touch on ovarian and germ
cell oncogenesis where this is appropriate. This section will
follow an outline. First a hierarchy of mechanistic considerations will be briefly reviewed proceeding from germ
cells (eggs and sperm) to chromosomes and DNA.
Germ cells
Sperm

The subject of cannabinoids and cancer is too large
to be reviewed in detail here. This and related subjects
have been described in several other publications to
which the interested reader is referred [45, 102–118].
Our intention here is merely to make some observations
which are of particular interest and illustrate how all
these seemingly disparate observations may present a
coherent conceptual framework of cannabinoid-related
carcinogenesis.

The luminal concentration of lipophilic testosterone
in the seminiferous tubules is known to be 100 times
higher than that in the serum and it is maintained at
these high levels in part by the blood testis barrier for
which the morphological basis is the tight junctions
between the supporting Sertoli cells which hold and
cradle and nurture the developing spermatids [119].
Anandamide, one of the major endocannabinoids,
is similarly concentrated in seminiferous tubules

Table 12 Ovarian Cancer – Predicted Regression Model Summaries
Linear Models
Parameter
Term

Model
Estimate (C.I.)

P_Value

Adj.R.Squared

S.D.

t-Value

P-Value

0.016 (0.0157, 0.0166)

2.52E-87

0.9811

0.0656

5185.35

2.52E-87

0.9944

0.0358

5898.511

1.31E-109

0.9991

0.0149

20,617.98

1.59E-142

Linear Model
Percentile

Cubic Polynomial Model
First Order
Percentile

4.728 (4.657, 4.799)

2.58E-111

Second
Order Percentile

−0.177 (−0.248, − 0.106)

3.15E-06

Third Order
Percentile

0.521 (0.449, 0.591)

3.91E-26

Quintic Polynomial Model
First Order
Percentile

4.728 (4.698, 4.757)

1.19E-145

Second
Order Percentile

−0.177 (−0.206, − 0.147)

1.45E-20

Third Order
Percentile

0.520 (0.491, 0.550)

3.85E-56

Fourth
Order Percentile

0.244 (0.215, 0.274)

1.43E-29

Fifth Order
Percentile

0.208 (0.178, 0.237)

7.22E-25

Term

Estimated Degrees of Freedom Residual
Degrees of
Freedom

statistic

P_Value Log.Likelihood Aliake
Information
Criterin

Bayesian Information
Criterion

Smoothened
Percentile

8.8097

8777.844

1.46E-19 273.484

−497.0799

GAM Models
Parameter

Model

8.9893

−525.3486
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Table 13 Ovarian Cancer – E-Values of Predicted Regression Models
Term

Estimate

Stamdard Error

Standard
Devaition

Relative Risk

E-Values

0.0161

0.0002

0.0656

1.251 (1.243, 1.258)

1.81, 1.79

First Order Percentile

4.7280

0.0357

0.0357

1.66E+ 52 (9.40E+ 50, 2.93E+ 53)

3.32E+ 52, 1.88E+ 51

Third Order Percentile

0.5208

0.0357

0.0357

5.65E+ 05 (3.21E+ 04, 9.98E+ 06)

1.13E+ 06, 6.41E+ 04

Linear Model
Percentile
Cubic Polynomial Model

Quintic Polynomial Model
First Order Percentile

4.7283

0.0149

0.0149

5.69E+ 125 (9.60E+ 124, 3.38E+ 126)

1.13E+ 126, 1.92E+ 125

Third Order Percentile

0.5208

0.0149

0.0149

7.12E+ 13 (1.21E+ 13, 4.23E+ 14)

1.43E+ 14, 2.40E+ 13

Fourth Order Percentile

0.2446

0.0149

0.0149

3.19E+ 06 (5.39E+ 05, 1.89E+ 07)

6.39E+ 06, 1.08E+ 06

Fifth Order Percentile

0.2084

0.0149

0.0149

3.48E+ 05 (5.87E+ 05, 2.06E+ 06)

6.96E+ 05, 1.17E+ 05

12.0 + 2.1 nM [120] (compared to 5.7 + 0.9pM in
serum [121]) where it acts to inhibit sperm activation,
acrosomal reaction and swimming and metabolism by
inhibiting mitochondrial respiration [65, 122, 123].
This makes sense because the sperm has limited metabolic reserves and penetration of the gransulosa cells
and zona pellucida surrounding the oocyte is very
difficult and requires hyperactivation of sperm motility in the context of the acrosomal reaction which
releases digestive enzymes into the thick proteoglycan layers surrounding the egg. Cannabinoids are also
suppressive to the hypothalamic release of LHRH,
to LH release and to testicular Leydig cell endocrine
function and thus acute serum testosterone levels
[124, 125].
Indeed cannabinoids in testicular and male reproductive tissue have been noted to have many actions including affecting DNA fragmentation, sperm DNA packing,
modification of sperm histones to sperm-specific variants
which facilitate their replacement by protamines which
are themselves tightly packed and heavily disulphidelinked cores for DNA wrapping, DNA nicking, DNA
repair, protection of DNA, and thus nuclear size determination [122, 126].
Sperm have a series of specialized histones which make
the genome more accessible and facilitate their replacement by protamines which allow much tighter DNA
packing [127]. Interestingly in sperm 5–10% of histones
remain in place and are not replaced by protamines
which is one mechanism by which transgenerational epigenetic inheritance occurs [128]. In one study differential
histone retention was only manifested in the F3 (grandchildren) generation [128].
Oocytes

Cannabinoids are found in the midcycle Graafian follicle
fluid and the midcycle oviduct fluid [122, 126].

Polycystic ovarian syndrome (PCOS) is a clinical syndrome characterized by menstrual irregularity, excess
androgens and sometimes ovarian cysts. It often accompanies obesity, may be complicated by systemic inflammation, impaired fertility and insulin resistance and may
be complicated by endometrial carcinoma [129]. It is
believed to have an heritable component. A fascinating
recent paper showed that the ovary itself was involved
in the dysregulated metabolic state and immune activation and that this was transmissible to a subsequent
generation of mice via a hypomethylated DNA methylome [130]. DNA hypomethylation has also been demonstrated in the offspring of mice prenatally exposed
to cannabis [117]. A characteristic gene signature was
observed including Robo1, CDKN1, HDC1, IGFBPL1
and IRST4 in both mouse F1 offspring and daughters of
human PCOS patients. Supplementation of the mice with
a methyl donor S-adenosyl-methionine (SAM) rescued
and reversed these changes [130]. Robo is also a key brain
morphogen which directs the exuberant neocortical outgrowth in human infants [131] and the Robo-slit system
has been shown to be inhibited by cannabinoids [132].
Certain features of this syndrome are reminiscent of
the changes seen in human females consuming cannabis
including the impaired fertility and altered reproductive hormones [124]. Moreover cannabinoids have been
shown to interact with Robo [132]. Like other tissues the
ovary will undergo increased methylation of CpG islands
in and near gene transcriptional start sites with age.
Epigenetic changes are known to be largely impacted
by metabolic processes as described above. Moreover
age-related decline in ovarian mitochondrial respiratory
function also occurs [133]. It has been shown that agerelated ovarian follicular failure in mice could be rescued
by dietary supplementation of coenzyme Q10 [134]. The
interaction between epigenomic, metabolic and immune
processes is well documented [130, 135–137].
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Chromosomes

Chromosomal damage is increasingly recognized as a
major cause of tumourigenesis generally [138–141].
As mentioned evidence of single stranded and double
stranded breaks in chromatin after cannabis exposure
have been provided by several classical studies including dramatic photomicrographs of chromosomes with
obvious breaks and gaps in them [142–145]. Pictures of
ring and long chains of four chromosomes have also been
described [146]. Indeed Stenchever found that the rate of
chromosomal breaks was 3.4% compared to 1.2% in control cells [145]. Evidence of whole genome doubling has
also been presented [143, 144] which is of particular relevance to testicular cancer where this is known to occur
as a major precursor genetic lesion [147, 148]. Leuchtenberger published dramatic photomicrographs showing
obviously lagging chromosomes in metaphase and anaphase spreads of dividing human lung cells [143]. These
are well known to be the morphological precursors of
micronucleus formation [149].
Micronuclei are known to be a major engine of
tumourigenesis and of birth defect induction when they
occur in germinative cells [138–141, 149–154]. For this
reason in vitro and in vivo micronucleus assays have
been foundational in genotoxicity testing and are written into the OECD genotoxicity testing Guidelines 474
and 487 [150].
Micronuclei are believed to arise either from aneugens
which break off pieces of the chromatid ends, or by clastogens which interfere with the action of the mitotic spindle and sister chromatid separation at anaphase [150]. A
further mechanism has been described involving nuclear
elongation [150]. It has recently been suggested that
nuclear mobilization, elongation and deformity may be
central to the mechanism by which cannabidiol induces
micronucleus formation [150].
Cannabinoids including THC, cannabidiol, cannabinol and cannabidivarin have been well demonstrated to
test positively in the micronucleus assay for many decades [146, 155–159]. Synthetic cannabinoids including AM-2201, UR-144, 5F-AKB-48, AM-2201-1C,
CP-478497-C8, RCS4, XLR-11, APINAC, BB-22, JWH018, JWH-018-CL and STS-135 also test positive in
micronucleus assays [160–163].
Nuclear blebs and chromosomal bridges are known to
be associated with micronucleus development [156] and
have been described after THC exposure in lymphocytes
and oocytes [60, 164]. Nuclear blebs and bridges are also
seen often in association with cannabinoid exposure
[150, 156].
Cannabis has long been known to test positively in the
micronucleus assay [158, 159]. Micronuclei are believed
to develop around chromosomes which become derailed
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from the mitotic spindle or lag behind and do not join
it and then become encapsulated in their own nuclear
envelope, where lacking the normal large complement
of enzymes usually involved in DNA functions they are
shattered by normal cell replicative processes [107, 115,
146, 149, 165–167]. Cannabis does this by interfering
with tubulin synthesis since the rails of the mitotic spindle are made of microtubules which are essentially greatly
elongated tubulin monomers [168]. For this reason cannabis has been designated as an indirect clastogen [115,
146, 165–167].
Importantly it has been shown that, along with many
other proteins, tubulin undergoes a variety of post-translational modifications including glycosylation, which
appear to affect its function, perhaps by giving it a subcellular address within the cell to target [169]. This “tubulin
code” is believed to function somewhat like the “histone
code”. Interruption of this glycation process interferes
with flagellar function and makes sperm swim in a circular pattern so that linear progress towards an oocyte
is impossible and fertility is greatly compromised. This is
believed to be a major factor in male infertility [169].
This implies that protein glycosylation is not only a
biomarker of various parameters but also a functional
readout of cell’s protein state. This finding supports the
previous call for protein glycosylation to be included
along with epigenomic markers in a potential biomarker
for cannabinoid exposure [109]. As cannabinoids penetrate increasingly into American society the need for a
quantitative biomarker to objectively define past cannabinoid exposure for both clinical and epidemiological
reasons becomes correspondingly greater.
DNA

It is well established that cannabinoids reduce cell growth
and reduce synthesis of the macromolecules of life such
as DNA, RNA and proteins including histones [30, 115,
146, 159, 165–167, 170–175]. Cannabinoids have been
shown to inhibit cell growth and division in all three layers of the embryo as well as haemopoietic and mesenchymal stem cells and their derivatives in osteoblastic,
adipoblastic, peripheral nerves and cutaneous adult tissues [171].
Cannabinoids including THC and cannabidiol have
been shown to oxidize the purine and pyrimidine bases
of DNA in a manner which is greatly amplified by metabolic activation which manifests due to the action of the
cytochrome oxidizing system of the liver such as occurs
normally in vivo [156, 176].
As mentioned evidence of single-stranded and doublestranded breaks in chromatin have been provided by
several classical studies including dramatic photomicrographs of chromosomes with obvious breaks and gaps in
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them ((Leuchtenberger1971, Leuchtenberger1973, Gilmour1971, Stenchever1974)). Indeed Stenchever found
that the rate of chromosomal breaks was 3.4% compared
to 1.2% in control cells ((Stenchever1974)).
Retrotransposon activation

Gestational toxin exposure to arsenic is known to induce
DNA hypomethylation in active retrotransposons mobilizing these mobile elements in the genome and leading
to genomic instability, cancer birth defects and mental
retardation which is transmissible to sperm and the following F1 generation [177].
DNA hypomethylation is also well described following
cannabis exposure [110, 117] and has also been shown to
be transmissible to sperm [110] and to the following generation where it may be detected in the Nucleus Accumbens of the brain [117].
It would appear feasible therefore that cannabinoidrelated hypomethylation could similarly mobilize repeat
elements in the human genome causing them to be replicated and to be inserted randomly into the genome
destabilising its integrity in a manner which is known to
lead to oncogenic destabilization.
Moreover some of the DNA material will leak into the
cytoplasm where it will trigger innate immunity via the
sensitive and powerful cyclic guanosyl monophosphate
- cyclic adenosine monophosphate synthase (cGAS) –
STimulator of INterferon Gamma (STING) pathway
which is powerfully proinflammatory [178]. Inflammatory and oxidizing milieus directly stimulate retrotransposon activation which makes the “jumping genes jump”
worse. Hence this sets up a positive feedback loop. This
pathway has been shown to be a powerful driver of both
innate immunity, tumour progression and aggressive
metastatic behaviour [178–184].
cGAS-STING pathway is also strongly stimulated by
micronuclei and their cytoplasmic rupture [181].
Such mechanisms may in part account for the numerous reports of aggressive cancers developing in young
patients who consume large amounts of cannabis [185–
188] and the many reports of widespread premalignant
field changes in the tissues of the upper aerodigestive
tracts [16, 20].
Generalization

We feel that our results are widely generalizable for a
number of reasons. The datasets comprising the foundation of this analysis are a national census cancer data
series, with age-standardization of cancer incidence rates
performed by CDC [68], and a large nationally representative annual widely quoted survey of drug use data
[189]. As noted above many of the present results have
been reported elsewhere in sources external to this study.
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The present bivariate analysis is at once conceptually
simple yet very powerful especially when paired with
E-Value calculations. For prostate and ovarian cancer
bivariate results were verified by further causal regression and space-time modelling which confirmed the
bivariate results and demonstrated overall robustness to
multivariable adjustment. One of the major result outputs from the present study was several E-Values which
constitute one of the major pillars of causal inference. We
feel that the large US datasets represent an ideal context
within which to address the present concerns. In that the
present results demonstrate causal relationships we are
confident that they could be widely reproduced with the
sole caveat that in nations where cannabis use is more
widespread we would expect the findings to be stronger
provided that the underlying datasets are sufficiently
accurate.

Strengths and limitations
This study has several strengths. A large national cancer
census dataset was used. Age adjusted rates derived from
CDC, SEER and NCI were employed. The drug dataset
was taken from a large well-validated nationally representative dataset. The bivariate statistics were straightforward and combined with the power of E-values they were
powerful to directly address. These studies were internally consistent and also and externally concordant with
known data both on tobacco-related cancer and on cannabis-related cancer. For the inferential modelling three
forms of inverse probability weighted regression were
employed with broadly consistent results. Geospacetime regression was also used to capture the inherently
spatiotemporal setting of the data including its inherently
complex spatially and temporally autocorrelated error
structure. Panelled graphs were used to allow the simultaneous display of results for direct comparison across
many cancer types.
In common with most epidemiological studies individual level participant data was not available to it.
State-level cannabinoid exposure had to be estimated as
described as state level data itself was also not directly
available. Another issue of considerable interest is the
possible role of synthetic cannabinoids as genotoxins. In
the absence of spatiotemporal data on this issue we are
unable to comment on this increasingly important matter. However several lines of evidence suggest that they
are likely to be implicated. Several recent studies implicate many cannabinoids in genotoxic activities [27, 28,
45, 100, 101, 156, 157, 190–192]. Long ago the genotoxic action was found to reside in the polycyclic olevitol nucleus of the cannabinoids with little modulation
by the various side chains [29, 190]. And several other
studies implicate synthetic cannabinoids in genotoxicity
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[160–163, 193–195]. Overall therefore we feel that this is
a fertile and important area for further laboratory based
investigation and epidemiological surveillance.
Furthermore this was also an ecological study. It is
therefore potentially susceptible to the short-comings
typical of ecological studies including the ecological fallacy and selection and information biases. Within the
present paper we began to address these issues with
the use of E-values in all Tables. This issue is further
addressed by the detailed pathophysiological mechanisms which have been described above, by mention
of other countries where many of the same findings
have been made, and with the use of inverse probability weighting in multiple regression models and further
extensive application of E-values in Parts 2 and 3 of the
present series of papers.

Conclusion
Strong bivariate relationships between cannabidiol exposure and prostate and ovarian cancer previously reported
[66, 67] were confirmed to be robust to multivariable
adjustment by mixed, panel, robust and spatiotemporal regression modelling. Mathematical modelling of the
relationship between increasing percentiles of cannabidiol exposure and prostate and ovarian cancer demonstrated strong evidence of a supra-linear sigmoidal
relationship between rising cannabidiol exposure and
cancer incidence such that increases in community cannabidiol exposure can be predicted to greatly and disproportionately increase tumour incidence. The implication
of both prostate and ovary (and also testicular in [3, 8, 10,
66, 101, 148, 196, 197]) cancers in this oncogenic portrait
carries very grave implications for community transmission of mutagenic and oncogenic genotoxicity from both
parental germ lines to subsequent generations. Further
work to investigate these themes in more detail and
increased depth and by groups working in related laboratory fields and epidemiological and statistical methodology is strongly indicated. The present study clearly
highlights the dangers of allowing increased cannabinoid
penetration into the community not only in terms of its
relationship to adult carcinogenesis but also in terms of
heritable and paediatric cancerogenesis and transgenerational transmission of mutagenic and oncogenic genotoxicity and epigenotoxicity and clearly demonstrates
supra-linear quasi-exponential dose- oncogenic-response
kinetics in population health profiles. Such results
strongly underscore the likely risks of increased cannabinoid penetration into the food chain which at the time of
writing has not been formally studied. The clear implication from the present work and its accompanying reports
[66, 67] is that community penetration of cannabinoids
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should be carefully restricted not only as a matter of public health and safety including importantly integrity of
the food chain, but also as a non-negotiable investment
in the genomic health and onco-protection of multiple
coming generations in a manner precisely analogous to
that of all other seriously genotoxic agents. Particular
concerns relate to the movement of increasing sections
of the community into higher dose ranges of cumulative cannabinoid exposure in the context of exponentiation of genotoxic dose-responses in higher dose ranges
which has now been convincingly demonstrated both in
the laboratory and in epidemiological studies of human
populations.
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